Past exam of the biochemistry and Molecular Biology course of the University of Cambridge / 2024 / Paper 1 / Section B

GDP–GTP exchange resets translation factors after GTP hydrolysis; it does not phosphorylate bound GDP back into GTP. A guanine nucleotide exchange factor lowers nucleotide affinity, allowing bound GDP to leave. The cytosolic nucleotide pool then supplies GTP. The GTP-bound and GDP-bound conformations bind different partners, while the ribosome and associated factors control when hydrolysis occurs. This couples repeated factor use to the ordered steps of biological translation.

During bacterial elongation, EF-Tu binds GTP and an aminoacyl-tRNA, delivering it to the ribosomal A site. Correct codon–anticodon recognition promotes rearrangements and GTPase activation. Hydrolysis and phosphate release permit EF-Tu departure and tRNA accommodation; rejection before and after hydrolysis contributes to kinetic proofreading. The GDP-bound factor is poorly suited to another delivery cycle until EF-Ts accelerates nucleotide exchange. Structural analysis of their complex showed disruption of the magnesium-binding environment, explaining reduced nucleotide affinity rather than a transfer of phosphate onto bound GDP.^[ref] The analogous eukaryotic delivery factor eEF1A is recycled by the eEF1B exchange machinery.

After peptide-bond formation, EF-G uses GTP in promoting bacterial ribosomal translocation; eEF2 performs the corresponding eukaryotic role. GDP release and GTP binding again regenerate active factor, but EF-G does not depend on EF-Ts for recycling in the way EF-Tu does: its nucleotide exchange is sufficiently rapid under physiological conditions. The contrast matters because “every translational GTPase requires its own exchange factor” would be incorrect. Different factors employ a common nucleotide switch with different exchange kinetics and regulatory partners.

Exchange also regulates initiation. eIF2–GTP carries initiating methionyl-tRNA in a ternary complex. Start-site recognition is coupled to its GTPase cycle and release in the GDP form; eIF2B supplies exchange for another round. Stress-induced phosphorylation of eIF2's alpha subunit inhibits productive exchange by eIF2B and lowers ternary-complex availability. Overall initiation falls, while particular messages with regulatory upstream open reading frames, including ATF4, can be translated more efficiently. Experiments manipulating those upstream reading frames establish how changing initiation-factor availability changes the choice of initiation site.^[ref] This is regulation of the rate of regeneration, not an alteration of the genetic code.

In bacterial termination, the RF3 GTPase assists recycling of class-I release factors; hydrolysis of peptidyl-tRNA itself is catalysed by the release factor, not directly by GTP cleavage. Likewise, peptide-bond formation draws on the activated ester linkage of charged tRNA, whose preparation consumed ATP. Approximately two elongation GTP molecules are used per incorporated residue, one for delivery and one for translocation, apart from initiation, termination and exceptional events. Nonhydrolysable GTP analogues, exchange-factor depletion and nucleotide-release measurements distinguish binding, hydrolysis and exchange. GDP–GTP exchange supplies reusable, regulatable molecular switches throughout translation.

Divergence preserves a structural framework while function changes; convergence produces similar solutions within otherwise different frameworks. Evidence should compare the entire protein fold, the sequence order and connectivity of structural elements, and the geometry of functional residues. Similar activity alone cannot distinguish either history, because many unrelated structures can perform the same reaction.

The globin fold illustrates divergence. myoglobin and the alpha and beta chains of haemoglobin share a predominantly alpha-helical architecture and a homologous pocket for haem. The proximal histidine coordinates the iron, and the surrounding pocket modulates ligand binding. Myoglobin is principally a monomeric oxygen-binding protein, whereas haemoglobin subunits interact within a tetramer to give cooperative oxygen transport. Their conserved core architecture and alignable sequence positions support descent from an ancestral globin, with duplication and subsequent specialization. Structural similarity remains recognizable even when many surface residues have changed. The functional difference arises partly from new intersubunit interactions rather than construction of an entirely new oxygen-binding chemistry.

Trypsin, chymotrypsin and elastase provide a second divergent series. They retain the chymotrypsin-like fold and corresponding catalytic triad residues, but changes in the specificity pocket favour different side chains next to the scissile peptide bond. A negatively charged pocket in trypsin favours basic residues; a hydrophobic pocket in chymotrypsin favours bulky aromatic residues; obstruction of the pocket in elastase favours smaller side chains. Conserved topology, residue correspondence and related sequences support common ancestry. The particular numbering of homologous catalytic residues is useful shorthand, but matching residue numbers alone is not evolutionary evidence.

For convergence, compare chymotrypsin-like proteases with subtilisin. Both are serine proteases using a serine nucleophile, histidine as a proton-transfer partner and an aspartate that organizes the histidine. Both stabilize a tetrahedral intermediate and form an acyl-enzyme. Nevertheless, their global folds differ, and the catalytic residues occur in different orders along the polypeptide: His–Asp–Ser in the chymotrypsin family and Asp–His–Ser in subtilisin. The similar local catalytic arrangement embedded in distinct topologies is evidence for independent assembly of effective serine-protease chemistry. Early three-dimensional structures made comparison of these spatial arrangements possible.^[ref]

The contrast is between a conserved scaffold with modified chemistry or specificity and independently organized scaffolds converging on a favourable active-site geometry. Chemical constraints help explain convergence: catalysis benefits from appropriately positioned acids, bases, nucleophiles and stabilizing charges. They do not require the rest of the protein to become similar.

Structural inference has limits. A common small motif can occur by chance or reflect physical constraints; failure to detect sequence similarity does not prove absence of ancient homology. Strong conclusions combine global structural alignment, sequence-profile comparisons, taxonomic distribution and molecular phylogeny. Domain duplication, rearrangement and loss can complicate a simple family tree. Thus structural resemblance is most persuasive when its extent and topology are evaluated alongside independent evolutionary evidence, rather than classifying every shared helix or catalytic residue as proof of common descent.

Selecting tight binding to a transition-state analogue is an ingenious route to catalytic activity, but it is an indirect and incomplete selection for a useful enzyme. A catalytic antibody can be raised against a stable molecule designed to resemble a reaction's transition state. Preferential stabilization of that configuration relative to the substrate can lower the activation free energy. In an early demonstration, antibodies elicited against suitable haptens catalysed ester hydrolysis and were inhibited by the corresponding transition-state analogues.^[ref] This established a principle of molecular recognition, rather than a guarantee that any tightly bound hapten yields efficient catalysis.

A stable analogue necessarily differs from the actual fleeting transition state. Antibody maturation selects affinity for the immunizing molecule, including groups used to attach it to a carrier, rather than directly selecting rapid repeated turnover of the desired substrate. A useful catalyst must position acid/base groups, exclude or organize water, control electrostatics, traverse all reaction intermediates and release products. Binding one geometrical approximation need not optimize those steps. Strong product binding can inhibit turnover; excellent affinity can coexist with a small turnover number. A large rate enhancement over an exceptionally slow uncatalysed reaction can still give an impractically slow absolute reaction. Limited substrate scope, difficult analogue synthesis and the production or stability requirements of an antibody scaffold add practical costs.

Performance must therefore be measured as product formation over multiple turnovers, with purified protein, no-antibody and unrelated-antibody controls, and suitable checks against contaminating enzymes. Report both turnover and substrate dependence, preferably catalytic efficiency, alongside stereoselectivity, stability and achievable substrate loading. Competitive inhibition by the immunizing hapten supports involvement of the binding site, but cannot by itself exclude every alternative source of activity.

Directed evolution instead mutates a gene, expresses a library and screens or selects the actual property required. Repeated selection of subtilisin E variants for activity in an organic solvent demonstrated improvement under the intended reaction conditions without requiring a complete mechanistic prediction of every mutation.^[ref] Starting from a natural enzyme supplies a scaffold already capable of catalytic turnover. The assay can jointly select activity, selectivity or stability, although improvements are only as relevant as the assay: better expression must not be mistaken for a better purified catalyst.

Contemporary computational enzyme design can place a modelled catalytic arrangement into a protein scaffold, then use experimental screening and directed evolution to improve it. Designed Kemp eliminases illustrate the combination of mechanistic design with subsequent empirical optimization.^[ref] Rational mutagenesis and recombination can likewise focus a library on useful positions. These methods still face imperfect models and finite search capacity; they succeed by testing catalysis more directly and iterating. The question's historical premise is best read as a loss of prominence of the classical hapten-immunization strategy, rather than proof that catalytic-antibody research has universally ceased. The decisive advance is selection for the reaction and operating conditions, with binding treated as one component of performance.